Dina Burkitbayeva, MBA

Dina Burkitbayeva is a leading entrepreneur and investor within the neuropsychiatric space. She currently serves as both the Co-Founder and CEO of Freedom Biosciences, a biotechnology company developing next-generation psychedelic and ketamine-based therapeutics for depression and other mental-health conditions, and as Co-Founder of PsyMed Ventures, a venture fund investing in cutting-edge mental-health and neurotechnology innovations. She began her career at McKinsey & Company and J.P. Morgan before turning to entrepreneurship and investing at the intersection of neuroscience and mental health. Dina holds an MBA from Harvard Business School and along with a B.S. and B.A. in City & Regional Planning and Economics from Cornell University.

Glenn Cohen, JD

I. Glenn Cohen is the James A. Attwood and Leslie Williams Professor of Law, Deputy Dean, and Faculty Director of the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics at Harvard Law School. He is widely recognized as a global authority on the interface of bioethics, health law, and medical innovation. His research spans topics including the therapeutic use of psychedelic drugs, medical AI, mobile health technologies, reproductive and transplantation ethics, and health policy. A member of the National Academy of Medicine, Professor Cohen has advised policymakers and industry leaders worldwide, and published extensively in leading law, medical, and science journals.

Jorge Quiroz, MD, MBA

Dr. Jorge Quiroz is the Chief Development and Strategy Officer at Gilgamesh Pharmaceuticals, where he leads the clinical and regulatory strategy for the company’s portfolio of innovative psychiatric therapies. He brings over 20 years of experience in drug development—spanning roles at the NIH, Johnson & Johnson, and Roche—covering the full spectrum from early-stage clinical research (IND filings and proof-of-concept studies) to registrational programs (NDA and sNDA submissions) for small molecules and gene therapies. Dr. Quiroz also holds an MBA from Columbia University/London Business School.

Jerrold Rosenbaum, MD

Dr. Jerrold Rosenbaum is a physician-scientist who is among the world’s leading authorities on mood and anxiety disorders, along with co-founding several neuropsychiatric biotechnology organizations. He currently serves as the Director of the Center for the Neuroscience of Psychedelics at the Massachusetts General Hospital (MGH), which seeks to understand how psychedelics impact the brain and elucidate potential therapeutic benefits of psychedelic therapies. He co-founded Sensorium, Psy Therapeutics, and Entheos Labs, organizations advancing innovative therapeutics within the neuropsychiatric space. In addition, Dr. Rosenbaum is the Stanley Cobb Professor of Psychiatry at Harvard Medical School and Psychiatrist‐in-Chief Emeritus of the Department of Psychiatry at MGH, where he led the department for two decades and oversaw hundreds of clinicians, researchers and trainees. Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Massachusetts General Hospital, Harvard Medical School.

Neeraj Koduri

Neeraj Koduri is a first-year student in the MS/MBA Biotechnology dual-degree program at Harvard Business School and the Harvard Graduate School of Arts and Sciences. Before HBS, he was a Senior Director on the Corporate Business Development Transactions team at Eli Lilly, leading M&A and partnership deals with emerging biotechnology companies. Prior to Lilly, Neeraj served as the Business Development and Strategy Lead at DICE Therapeutics, an immunology focused biotech, supporting the company through its IPO and eventual sale to Lilly. He began his career in life sciences investment banking at Wells Fargo Securities and biotechnology equity research at Evercore ISI. Neeraj earned his undergraduate degree from the University of Southern California.

Alexa Tucker

Alexa Tucker is currently a first-year student in the MS/MBA in Biotechnology dual degree program at HBS/Harvard GSAS. Alexa began her career in life sciences strategy consulting at ClearView Healthcare Partners before transitioning into the biopharmaceutical industry in a business development role at Alkermes. Alexa became interested in the unique opportunities and barriers facing novel drug development in the neuropsychiatric space while evaluating opportunities for potential in-licensing or acquisition at Alkermes. Alexa holds a B.A. from Dartmouth College.